Cardiovascular Research, Год журнала: 2022, Номер 118(18), С. 3401 - 3402
Опубликована: Дек. 7, 2022
Heart failure remains a leading cause of morbidity and mortality globally.Within the last 5 years, many new developments have been seen in area heart failure, including completely therapies, mechanistic insights, as well novel strategies to phenotype segment condition.Ten reviews two original articles provide an updated overview on specific failure.
Язык: Английский
Circulation, Год журнала: 2024, Номер 149(22), С. 1729 - 1748
Опубликована: Март 15, 2024
Myocardial infarction (MI) and heart failure are associated with an increased incidence of cancer. However, the mechanism is complex unclear. Here, we aimed to test our hypothesis that cardiac small extracellular vesicles (sEVs), particularly mesenchymal stromal cell-derived sEVs (cMSC-sEVs), contribute link between post-MI left ventricular dysfunction (LVD)
Язык: Английский
Процитировано
18
Cancers, Год журнала: 2023, Номер 15(3), С. 729 - 729
Опубликована: Янв. 25, 2023
Within the aging population, frequency of cancer is increasing dramatically. In addition, multiple genetic and environmental factors lead to common multifactorial diseases, including cardiovascular disease, chronic kidney obstructive pulmonary metabolic-associated fatty liver disease. recent years, there has been a growing awareness connection between as well how one can affect other, resulting in vicious cycle. Although exact mechanistic explanations behind this remain be fully explored, some progress made uncovering pathologic mechanisms. review, we focus on nature link conditions, specific shared mechanisms, which may represent either preventive or therapeutic targets. Rather than organ-specific interactions, herein mechanisms among explain increased risk. More research subject will highlight significance developing new drugs that target systems rather just
Язык: Английский
Процитировано
20
Cardiovascular Research, Год журнала: 2024, Номер 120(6), С. 612 - 622
Опубликована: Фев. 22, 2024
Heart failure (HF) and cancer are the leading causes of death worldwide. Epidemiological studies revealed that HF patients prone to develop cancer. Preclinical provided some insights into this connection, but exact mechanisms remain elusive. In colorectal (CRC), gut microbial dysbiosis is linked progression recent have shown display dysbiosis. This current study focussed on effects HF-induced colonic tumour formation.
Язык: Английский
Процитировано
6
European Heart Journal Open, Год журнала: 2023, Номер 3(5)
Опубликована: Авг. 3, 2023
The association between heart failure (HF) patients and the incidence of cancer is not well understood, with conflicting results to date. aim this meta-analysis was evaluate whether HF have a higher risk developing cancer.We performed systematic literature search using PubMed, Embase, Scopus for relevant articles from inception until 10 December 2022. primary clinical outcome cancer. Secondary endpoints were breast cancer, lung haematological colorectal prostate A total 9 7 329 706 (515 041 vs. 6 814 665 non-HF) involved in analysis. mean age non-HF groups 69.06 66.76 years. median follow-up duration 6.7 most common comorbidity among both includes diabetes mellitus (27.58 14.49%) hypertension (81.46 57.38%). Patients associated significant increase {hazard ratio [HR], 1.43 [95% confidence interval (CI): 1.21-1.68], P < 0.001}, [HR, 1.28 (95% CI: 1.09-1.50), 0.001], 1.89 1.25-2.85), 1.63 1.15-2.33), = 0.01], 1.32 1.11-1.57), 0.001] compared without HF. However, comparable 0.97 0.66-1.43), 0.88].This confirms that state incident These data may aid raising awareness physicians develop prevalent early screening evaluation be useful an diagnosis
Язык: Английский
Процитировано
15
Cancers, Год журнала: 2024, Номер 16(8), С. 1450 - 1450
Опубликована: Апрель 9, 2024
Cancer and cardiovascular disease are the two most common causes of death worldwide. As fields medicine oncology continue to expand, area overlap is becoming more prominent demanding dedicated attention individualized patient care. We have come realize that both inextricably intertwined in several aspects, so much mere presence one, with its resultant downstream implications, has an impact on other. Nonetheless, cancer generally approached independently. The focus granted predominant pathological entity (either or cancer), does not allow for optimal medical care a result, ample opportunities improvement overall health being overlooked. Herein, we hope shed light interconnected relationship between uncover some unintentionally neglected intricacies therapeutics from oncologic standpoint.
Язык: Английский
Процитировано
4
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 8, 2025
Язык: Английский
Процитировано
0
Medicina, Год журнала: 2025, Номер 61(2), С. 301 - 301
Опубликована: Фев. 10, 2025
Background and Objectives: Cardio-oncology addresses the growing concern of cardiovascular complications arising from cancer therapies. Although treatments have greatly enhanced survival outcomes, they frequently carry substantial risks to health. This research examines toxicity associated with HER2-targeted therapies, focusing on interconnection between tumor characteristics, including histopathological profiles TNM classification, development complications. The objective is identify key correlations that inform better prevention management strategies for cardiotoxicity in oncology patients. Materials Methods: retrospective study analyzed patients undergoing cytostatic treatments, particularly anthracyclines, radiotherapy, Cardiac function was monitored using echocardiographic assessments, global longitudinal strain left ventricular ejection fraction (LVEF). Patients were stratified based staging findings evaluate treatment regimens outcomes. Results: analysis revealed a significant association advanced stages reduced LVEF, stage T4 showing highest prevalence cardiac dysfunction. Cytostatic such as anthracyclines identified contributors cardiotoxicity, advanced-stage These emphasize importance regular monitoring detect early signs pre-existing risk factors demonstrated higher Conclusions: highlights need personalized approaches tailored cardioprotective improve outcomes enhance quality life Future studies should prioritize developing improved reduce linked contemporary treatments.
Язык: Английский
Процитировано
0
Antibiot Khimioter = Antibiotics and Chemotherapy, Год журнала: 2025, Номер 69(9-10), С. 91 - 107
Опубликована: Фев. 10, 2025
An analysis of the literature for 2022 was carried out in order to study latest data on cardiotoxicity antitumor drugs. The abundance pathogenesis even a single chemotherapeutic agent indicates multifactorial effect and characteristics individual sensitivity each patient particular drug. Due nature cardiotoxicity, clinical manifestations this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases before tumor development, cancer progression without therapeutic intervention, or it, can cause cardiac side effects. To identify such processes, it is necessary monitor cardio-oncological dynamics. When conducting conservative treatment event development effects, complete cancellation impossible, as continue therapy, well repeat its courses, often throughout patient's life. In regard, methods needed reduce severity cardiotoxic effect, suppress adverse effects anticancer drugs myocardium, search effective prevention chemotherapy still relevant. Timely detection, hence, prevention, reduction degree damaging beginning when using agents possible only with close cooperation between oncologists cardiologists.
Язык: Английский
Процитировано
0
Journal of Cardiac Failure, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
American Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown, С. 100928 - 100928
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0